NEW YORK, May 18, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, the company's chairman and CEO, will be presenting at the Seventh Annual Neurotech Investing and Partnering Conference.
The title of Dr. Chain's presentation is "Prefibrillar Tau Neoepitopes Offer Attractive Targets for Active and Passive Immunotherapy." His presentation will take place on May 21st at the Intercontinental Hotel in Boston from 10:15-11:30 AM (EDT), as part of the session entitled "Alzheimer's and Cognitive Disorders."
"Intellect Neurosciences is at the forefront of Alzheimer's research, with a rich pipeline and intellectual property portfolio and licensed products in late-stage clinical development," said Dr. Chain. "We embrace opportunities like this one and realize they are essential toward raising additional awareness of our technology, our work in developing ground-breaking treatments for Alzheimer's and other devastating neurodegenerative diseases."
About The Neurotech Investing and Partnering Conference
The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.
About Intellect Neurosciences
Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neuro
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved